Streetwise Reports' Article Archives — October 2016 back to current month (35)
Calling an end to the correction in silver is tricky, but technical analyst Clive Maund sees an intermediate base forming for silver stocks, a "classic buy spot."
Technical analyst Clive Maund outlines why he believes the correction in gold and precious metals stocks is coming to an end.
Jack Chan: This Past Week in Gold (10/29/2016)
Technical analyst Jack Chan charts the last week's movements in the gold and silver markets.
Alkane Resource's flagship Dubbo Zirconium Project moved closer to production after the company announced a Memorandum of Understanding between its wholly owned subsidiary Australian Zirconia and German engineering and technology giant Siemens.
New PEA for Seabridge's KSM Is a Game-Changer (10/27/2016)
Calling the new preliminary economic assessment for Seabridge Gold's KSM "a big improvement for a unique massive Au-Cu project," Paradigm Capital believes the company will continue to build value for investors.
Ben Kramer-Miller, chief analyst at miningWEALTH, notes that Santacruz Silver Mining has been a top pick since March, and while shares have risen ~70%, he still believes there is substantial upside ahead.
Precious metals expert Michael Ballanger discusses his favorite investing books and reviews the landscape for gold and the U.S. dollar between now and the end of the year.
Saudi Arabia's Oil Minister Khalid al-Falih declared the cycle of low crude prices is nearing an end as the oil market strengthens in recent weeks.
Jack Chan: This Past Week in Gold (10/22/2016)
Technical analyst Jack Chan charts recent movements in the gold and silver markets. With COT data showing signs of a bottom, Chan is waiting for price action to confirm.
Three Resource Equities That Are Worth a Closer Look (10/21/2016)
Money manager Adrian Day looks at three resource companies with recent developments and examines how those developments affect the companies and whether the stocks are good buys.
Exploring Solutions to Healthcare's Spending Crisis (10/19/2016)
Rising healthcare costs continue to preoccupy providers, patients, politicians and investors. Some cost increases stem from inefficiencies in the medical system, some from social and demographic trends, and others are a function of profit motives on the part of insurers and a few drug companies. In this article for The Life Sciences Report, Dr. Len Yaffe of Stoc*Doc Partners reviews the issues and proposes some cures.
It's Rally Time for Gold and Silver Equities (10/19/2016)
Precious metals expert Michael Ballanger discusses the uptick in gold and silver miners and the Deutsche Bank gold bullion settlement.
Production numbers were lower than expected for Q3/16, but analysts following Great Panther Silver remain buoyed both by the company's financial strength and silver output from its Guanajuato Mine Complex.
Tocqueville Asset Management invests in precious metals companies for the long term, looking for names that are innovative and creative in identifying properties and adding value to those properties, says Portfolio Manager and Senior Research Analyst Doug Groh. Geopolitical and financial concerns, as well as market fundamentals, favor gold over the longer term, he believes. In this interview with The Gold Report, Groh provides his analysis of the macro environment for precious metals and profiles seven companies with quality assets that he expects to create value.
Jack Chan: This Past Week in Gold and Silver (10/15/2016)
Technical analyst Jack Chan charts the latest moves in gold and silver markets, noting COT data is showing signs of a bottom.
Four Companies for the Metals Market Turnaround (10/13/2016)
The bear market was tough. Lots of companies went into complete hibernation; lots of people left the sector. It takes time for companies to get going again, but they have begun to get back on their feet, says Gwen Preston, founder of Resource Maven. She discusses some of the major trends she sees in the mining industry, and profiles several companies that survived the lean years and could lead the pack going forward.
Tiptoeing Back into the Miners (10/13/2016)
Precious metals expert Michael Ballanger explains why he sees a "bottom in the cards," and outlines a trading plan to capitalize on the turnaround.
Ben Kramer-Miller, chief analyst at miningWEALTH, profiles Globex Mining Enterprises, which has a royalty on a zinc mine that has the potential to create a sizeable amount of cash flow.
Bob Moriarty of 321 Gold discusses how best to play the correction currently underway in the precious metals markets.
Contrary to what a number of gold bugs have observed, other experts believe recent drops in the gold price are not a bull market correction, but rather reflect a market stuck in a commodity bear "super-cycle." Coupled with a gloomy end-of-year outlook for stock markets, precious metals and miners could be in for a rough Q4.
Two Resource Companies Advancing Toward Goals (10/09/2016)
Money manager Adrian Day discusses two companies in his portfolio that he says have had meaningful recent developments, both positive and negative, and that he deems good buys.
Jack Chan: This Past Week in Gold (10/08/2016)
Technical analyst Jack Chan charts the latest movement in the gold and silver markets, noting the cycle has reversed down.
In the last month, Millennial Lithium has moved to acquire projects in two large land packages in Argentina's "Lithium Triangle," as demand for the metal is expected to skyrocket.
NOVAGOLD's third quarter financial results show a balance sheet that should be sufficient to complete permitting of the Donlin Gold project in Alaska, according to National Bank Financial.
Gold Bull Still Intact, Use Pullback to Accumulate (10/06/2016)
This week's drop in the gold price has spooked many investors, says money manager Adrian Day, who provides his perspective on the volatility.
By assigning CUSIP numbers to physical precious metal assets, including gold and silver bar bullion, Delaware Depository and CUSIP Global Services have made it easier for investors to trade and track the commodities on traditional platforms.
Analysts Keep Focus on DURECT's DUR-928 (10/06/2016)
The FDA's recent Complete Response Letter for Remoxy, which is licensed by DURECT to Pain Therapeutics, has not changed the view of several analysts who follow DURECT. They are focused on DUR-928 for NASH and impaired kidney function, indications that are of great interest to Big Pharma.
Private-pay aesthetic procedures constitute a trend in medical devices, according to Anthony Vendetti, Director of Research at Maxim Group. These nonreimbursable types of procedures have seen rapid growth in the past decade. In this interview with The Life Sciences Report, Vendetti discusses Viveve Medical, which is attempting to leapfrog the competition to get FDA approval to use its patented radiofrequency technology to improve women's sexual function.
Gold Falls on Rate-Hike Fears (10/04/2016)
Gold fell below $1,300 today for the first time since the Brexit vote in June, as the dollar index rose to a two-month high.
Precious metals expert Michael Ballanger assesses the gold-silver ratio and its ramifications for the market.
Gold in Japan, the Last Frontier (10/02/2016)
Bob Moriarty of 321 Gold discusses Southern Arc Mineral's large stake in Japan Gold Corp., a new company positioned to take advantage of Japan's opening of gold exploration to foreign companies.
Is Deutsche Bank Another Lehman? (10/02/2016)
Technical analyst Clive Maund discusses whether Deutsche Bank's derivative book could derail the market, and he reviews precious metals and recent holdings.
Another Banking Crisis Begins? (10/02/2016)
Rudi Fronk and Jim Anthony, co-founders of Seabridge Gold, discuss Deutsche Bank's latest movements and what a bailout could look like.
Jack Chan: This Past Week in Gold (10/01/2016)
Technical analyst Jack Chan charts current movements in the gold and silver markets, noting that the cycle has turned up and prompted moderate investment.
Jack Chan: This Past Week in Oil (10/01/2016)
Technical analyst Jack Chan charts recent movements in the oil markets, noting that the cycle has turned up and a major new buy signal has been confirmed.
|"GBR is one of the most active, well-financed junior explorers."|
|"DRRX's psoriasis trial is on target for topline data by year-end 2019."|
|"This looks like an excellent time to take positions in NRG."|
|"We are adding LIO to our formal Watch List after meeting management."|
|"We highlight the considerable exploration upside at MAG's Juanicipio."|